Evolus, Inc. EOLS
7.42 USD +0.61 (+8.96%)
At closeNov 11, 2026, 4:43 PM EST
7.42 0.00 0.00%
After hours · Nov 11, 4:43 PM ET
6.85 Day range 7.44
3.94 52-week range 9.30
- YTD
- +11.58%
- 1 year
- +6.15%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact…
seekingalpha.com Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript
marketbeat.com What Evolus (EOLS) Said on Its Q3 Earnings Call Evolus NASDAQ: EOLS reported third-quarter revenue of $78 million, up 13% from a year earlier, as sales of its injectable products grew and the company posted its fourth consecutive quarter of…
zacks.com Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates Evolus, Inc. (EOLS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.14 per share a year ago.
benzinga.com Evolus Q3 2026 Earnings Call Transcript Evolus (NASDAQ:EOLS) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Evolus Affirms FY2026 Sales Guidance of $330.000M-$337.000M vs $334.100M Est Evolus (NASDAQ:EOLS) affirms FY2026 sales outlook from $330.000 million-$337.000 million to $330.000 million-$337.000 million vs $334.100 million estimate.
benzinga.com Evolus Q3 EPS $(0.19) Misses $(0.17) Estimate, Sales $78.000M Beat $77.662M Estimate Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 18.75 percent. This is a 72.73 percent decrease over losses of $(0.11)…
businesswire.com Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact…
businesswire.com Evolus to Participate in Upcoming Investor Conferences in New York and London NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact…
businesswire.com Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it…
gurufocus.com EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law [url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
businesswire.com EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $EOLS--EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to…
benzinga.com Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug The U.S. Food and Drug Administration's Office of Prescription Drug Promotion in September issued a warning letter to Evolus Inc. (NASDAQ:EOLS) regarding misleading Instagram promotional posts for…
benzinga.com Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug The FDA has warned Evolus that an Instagram post for Jeuveau is false or misleading and misbrands the drug.
businesswire.com Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the launch…
benzinga.com Reported Earlier, Telix Names David Gill Board Chair As Mark Nelson Steps Down From Interim Role Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix" or the "Company") today announces that David Gill has been appointed Chair of the Board, effective immediately.Mr. Gill joined Telix as a
benzinga.com HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $13 price target.- benzinga.com Evolus Q2 EPS $(0.12), Sales $84.084M Beat $81.603M Estimate Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 0 percent. This is a 47.83 percent increase over losses of $(0.23) per…
- benzinga.com Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est Evolus (NASDAQ:EOLS) raises FY2026 sales outlook from $327.000 million-$337.000 million to $330.000 million-$337.000 million vs $330.445 million estimate.
- benzinga.com Evolus Enters Into Exclusive Licensing And Distribution Agreement With IBSA To Develop And Commercialize Profhilo In US Evolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and…
benzinga.com Evolus Files Prospectus To Offer Up To $250M Of Securities https://www.sec.gov/Archives/edgar/data/1570562/000157056226000071/evoluss-32026.htm
benzinga.com Evolus Affirms FY2026 Sales Guidance of $327.000M-$337.000M vs $330.020M Est Evolus (NASDAQ:EOLS) affirms FY2026 sales outlook from $327.000 million-$337.000 million to $327.000 million-$337.000 million vs $330.020 million estimate.
benzinga.com Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 results, cuts FY guidance. Other stocks also down.
benzinga.com Earnings Scheduled For May 4, 2026 
benzinga.com Why eBay Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, valuing GME at $55.5B. eBay shares jumped 8.1% to $112.50 in pre-market trading.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For March 3, 2026
benzinga.com Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com Earnings Scheduled For May 7, 2025
benzinga.com This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com Earnings Scheduled For March 4, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session